Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: A phase I/II report

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Fan, Hui ^a   Lu, Xuechun ^a   Wang, Xiaohui ^a   Liu, Yang ^a   Guo, Bo ^a   Zhang, Yan ^a   Zhang, Wenying ^a   Nie, Jing ^a   Feng, Kaichao ^a   Chen, Meixia ^a   Zhang, Yajing ^a   Wang, Yao ^a   Shi, Fengxia ^a   Fu, Xiaobing ^a   Zhu, Hongli ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA METHYLTRANSFERASE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL THERAPY; CERVICAL SQUAMOUS CELL CARCINOMA; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISEASE COURSE; DNA EXTRACTION; DNA METHYLATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; GASTRIC CARDIA ADENOCARCINOMA; HEPG2 CELL LINE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPERHIDROSIS; INTRAHEPATIC BILE DUCTS ADENOCARCINOMA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR SURGERY; MALE; MALIGNANT PLEURAL TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; OVARY SEROUS PAPILLARY CYSTADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REFRACTORY ADVANCED SOLID TUMOR; RNA ISOLATION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBAL SEROUS ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TRANSPLANTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARCINOMA; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 84902201862     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/371087     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Longley D. B., Johnston P. G., Molecular mechanisms of drug resistance. Journal of Pathology 2005 205 2 275 292 2-s2.0-13644254794 10.1002/path.1706 (Pubitemid 40227997)
3. Berger S. L., Kouzarides T., Shiekhattar R., Shilatifard A., An operational definition of epigenetics. Genes and Development 2009 23 7 781 783 2-s2.0-64349095390 10.1101/gad.1787609
4. Sharma S., Kelly T. K., Jones P. A., Epigenetics in cancer. Carcinogenesis 2009 31 1 27 36 2-s2.0-74049141478 10.1093/carcin/bgp220
5. Taby R., Issa J.-P., Cancer epigenetics. CA Cancer Journal for Clinicians 2010 60 6 376 392 2-s2.0-78649383152 10.3322/caac.20085
6. Gomes A., Reis-Silva M., Alarcao A., Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Revista Portuguesa de Pneumologia 2014 20 1 20 30
7. Peedicayil J., The role of DNA methylation in the pathogenesis and treatment of cancer. Current Clinical Pharmacology 2012 7 4 333 340
8. Sang M., Wu X., Fan X., Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomarkers 2014 19 1 34 42
9. Gurion R., Vidal L., Gafter-Gvili A., Yeshurun Y. B., Raanani P., Shpilberg O., 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis. Haematologica 2010 95 2 303 310 2-s2.0-76549092572 10.3324/haematol.2009.010611
10. Cashen A. F., Schiller G. J., O'Donnell M. R., DiPersio J. F., Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute Myeloid Leukemia. Journal of Clinical Oncology 2010 28 4 556 561 2-s2.0-77449149374 10.1200/JCO.2009.23.9178
11. Gnyszka A., Jastrzebski Z., Flis S., DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Research 2013 33 8 2989 2996
12. Kelly T. K., de Carvalho D. D., Jones P. A., Epigenetic modifications as therapeutic targets. Nature Biotechnology 2010 28 10 1069 1078 2-s2.0-77957937450 10.1038/nbt.1678
13. Blum W., Klisovic R. B., Hackanson B., Liu Z., Liu S., Devine H., Vukosavljevic T., Huynh L., Lozanski G., Kefauver C., Plass C., Devine S. M., Heerema N. A., Murgo A., Chan K. K., Grever M. R., Byrd J. C., Marcucci G., Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology 2007 25 25 3884 3891 2-s2.0-34548529948 10.1200/JCO.2006.09.4169 (Pubitemid 47477265)
14. Wang L.-X., Mei Z.-Y., Zhou J.-H., Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T Lymphocyte Responses. PLoS ONE 2013 8 5 e62924
15. Wijermans P., Lübbert M., Verhoef G., Bosly A., Ravoet C., Andre M., Ferrant A., Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Journal of Clinical Oncology 2000 18 5 956 962 2-s2.0-17444452612 (Pubitemid 30123770)
16. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., Faderl S., Bueso-Ramos C., Ravandi F., Estrov Z., Ferrajoli A., Wierda W., Shan J., Davis J., Giles F., Saba H. I., Issa J.-P. J., Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007 109 1 52 57 2-s2.0-33846011361 10.1182/blood-2006-05-021162 (Pubitemid 46053042)
17. Chu B. F., Karpenko M. J., Liu Z., Phase I study of 5-aza-2′- deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2013 71 1 115 121
18. Kopp L. M., Ray A., Denman C. J., Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Molecular Immunology 2013 54 3-4 296 301
19. Zhang Y., Wang J., Wang Y., Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clinical and Developmental Immunology 2013 2013 12 195691 10.1155/2013/195691
20. Esteller M., Corn P. G., Baylin S. B., Herman J. G., A gene hypermethylation profile of human cancer. Cancer Research 2001 61 8 3225 3229 2-s2.0-0035870248 (Pubitemid 32695003)
21. Lotem J., Sachs L., Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 2006 25 59 7663 7672 2-s2.0-33845712622 10.1038/sj.onc.1209816 (Pubitemid 44967961)
22. Hirata H., Hinoda Y., Nakajima K., Kawamoto K., Kikuno N., Ueno K., Yamamura S., Zaman M. S., Khatri G., Chen Y., Saini S., Majid S., Deng G., Ishii N., Dahiya R., Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. International Journal of Cancer 2011 128 8 1793 1803 2-s2.0-79951986031 10.1002/ijc.25507
23. Chun S. G., Zhou W., Yee N. S., Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biology & Therapy 2009 8 14 1328 1339 2-s2.0-76249090605
24. Lundqvist A., Abrams S. I., Schrump D. S., Alvarez G., Suffredini D., Berg M., Childs R., Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Research 2006 66 14 7317 7325 2-s2.0-33746917919 10.1158/0008-5472.CAN-06-0680 (Pubitemid 44197714)
25. Fonsatti E., Nicolay H. J. M., Sigalotti L., Calabrò L., Pezzani L., Colizzi F., Altomonte M., Guidoboni M., Marincola F. M., Maio M., Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clinical Cancer Research 2007 13 11 3333 3338 2-s2.0-34250621776 10.1158/1078-0432.CCR-06-3091 (Pubitemid 46944920)
26. Samlowski W. E., Leachman S. A., Wade M., Cassidy P., Porter-Gill P., Busby L., Wheeler R., Boucher K., Fitzpatrick F., Jones D. A., Karpf A. R., Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. Journal of Clinical Oncology 2005 23 17 3897 3905 2-s2.0-21244449980 10.1200/JCO.2005.06.118 (Pubitemid 46218692)
27. Vigil C. E., Martin-Santos T., Garcia-Manero G., Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Design, Development and Therapy 2010 4 221 229 2-s2.0-79952050717 10.2147/DDDT.S3143
28. Stathis A., Hotte S. J., Chen E. X., Hirte H. W., Oza A. M., Moretto P., Webster S., Laughlin A., Stayner L.-A., McGill S., Wang L., Zhang W.-J., Espinoza-Delgado I., Holleran J. L., Egorin M. J., Siu L. L., Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical Cancer Research 2011 17 6 1582 1590 2-s2.0-79952710830 10.1158/1078-0432.CCR-10-1893
29. George R. E., Lahti J. M., Adamson P. C., Zhu K., Finkelstein D., Ingle A. M., Reid J. M., Krailo M., Neuberg D., Blaney S. M., Diller L., Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a children's oncology group study. Pediatric Blood and Cancer 2010 55 4 629 638 2-s2.0-77957039745 10.1002/pbc.22607
30. Appleton K., Mackay H. J., Judson I., Plumb J. A., McCormick C., Strathdee G., Lee C., Barrett S., Reade S., Jadayel D., Tang A., Bellenger K., Mackay L., Setanoians A., Schätzlein A., Twelves C., Kaye S. B., Brown R., Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of Clinical Oncology 2007 25 29 4603 4609 2-s2.0-34548414620 10.1200/JCO.2007.10.8688 (Pubitemid 350035319)
31. Yoo C. B., Jones P. A., Epigenetic therapy of cancer: past, present and future. Nature Reviews Drug Discovery 2006 5 1 37 50 2-s2.0-33644856123 10.1038/nrd1930
32. Issa J.-P. J., DNA methylation as a therapeutic target in cancer. Clinical Cancer Research 2007 13 6 1634 1637 2-s2.0-34250213859 10.1158/1078-0432.CCR-06-2076 (Pubitemid 46952927)
33. Jabbour E., Issa J.-P., Garcia-Manero G., Kantarjian H., Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008 112 11 2341 2351 2-s2.0-52049102456 10.1002/cncr.23463
34. Karahoca M., Momparler R. L., Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 2013 5 1, article 3
35. Bauman J., Verschraegen C., Belinsky S., Muller C., Rutledge T., Fekrazad M., Ravindranathan M., Lee S.-J., Jones D., A phase i study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology 2012 69 2 547 554 2-s2.0-84856718345 10.1007/s00280-011-1729-2
36. Schrump D. S., Fischette M. R., Nguyen D. M., Zhao M., Li X., Kunst T. F., Hancox A., Hong J. A., Chen G. A., Pishchik V., Figg W. D., Murgo A. J., Steinberg S. M., Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clinical Cancer Research 2006 12 19 5777 5785 2-s2.0-33750326078 10.1158/1078-0432.CCR-06-0669 (Pubitemid 44629609)
37. Krishnadas D. K., Bao L., Bai F., Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumor Biology 2014 10.1007/s13277-014-1764-9
38. Santini V., Kantarjian H. M., Issa J.-P., Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Annals of Internal Medicine 2001 134 7 573 586 2-s2.0-0035799382 (Pubitemid 32245319)